Process for preparing pyrazole functionalized benzodiazepinones
    1.
    发明申请
    Process for preparing pyrazole functionalized benzodiazepinones 审中-公开
    制备吡唑官能化苯并二氮杂酮的方法

    公开(公告)号:US20090203901A1

    公开(公告)日:2009-08-13

    申请号:US12378363

    申请日:2009-02-12

    摘要: The present invention provides innovative strategies for synthesizing pyrazole ring-functionalized benzodiazepinones. Alternative intermediates and high conversion strategies for forming alpha-aminobenzophenone intermediates involve a combination of aromatic acylation, displacement of electronegative leaving groups with amine, and then N-displacement strategies to produce the desired alpha-aminobenzophenone with primary amine functionality. Reaction strategies are then provided for converting alpha-aminobenzophenones to alpha-aminoamidobenzophenone intermediates with high yield and convenient reaction strategies. These alpha-aminoamidobenzophenone intermediates are then converted into benzodiazepinones. These benzodiazepinones are then converted to pyrazole ring functionalized benzodiazepinones through a series of innovative intermediates and/or reaction strategies.

    摘要翻译: 本发明提供用于合成吡唑环官能化苯并二氮杂酮的创新策略。 用于形成α-氨基二苯甲酮中间体的替代中间体和高转化策略涉及芳族酰化,负电离离子基团与胺的置换,然后是N-位移策略以产生具有伯胺官能团的所需α-氨基二苯甲酮的组合。 然后提供反应策略,以高产率和方便的反应策略将α-氨基二苯甲酮转化为α-氨基氨基二苯甲酮中间体。 然后将这些α-氨基氨基二苯甲酮中间体转化为苯并二氮杂酮。 然后通过一系列创新的中间体和/或反应策略将这些苯并二氮杂酮转化成吡唑环官能化的苯并二氮杂酮。

    Preparation of mibefradil via an acetamide anion
    4.
    发明授权
    Preparation of mibefradil via an acetamide anion 失效
    通过乙酰胺阴离子制备米非拉迪

    公开(公告)号:US5808088A

    公开(公告)日:1998-09-15

    申请号:US60151

    申请日:1998-04-14

    IPC分类号: C07D235/14

    CPC分类号: C07D235/14

    摘要: A method of preparing 2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino)}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate comprises contacting 6-fluoro-1-isopropyl-3,4-dihydro-1H-naphthalen-2-one with the dianion of N-�3-(1H-benzimidazol-2-yl)propyl!-N-methylacetamide to form N-�3-(1H-benzimidazol-2-yl)propyl!-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide, reducing this to 2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol, and treating the 2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol with methoxyacetic acid or an activated derivative of methoxyacetic acid. The invention is particularly applicable to the preparation of mibefradil, (lS,2S)-2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate, and its dihydrochloride salt. N-�3-(1H-Benzimidazol-2-yl)propyl!-N-methylacetamide, and the acetic acid solvate of 2-�2- {�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol dioxalate, are new.

    摘要翻译: 制备2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}}乙基] -6-氟-1-异丙基-1,2,3,4-四氢化萘-2 - 甲氧基乙酸甲酯包括使6-氟-1-异丙基-3,4-二氢-1H-萘-2-酮与N- [3-(1H-苯并咪唑-2-基)丙基] -N-甲基乙酰胺 形成N- [3-(1H-苯并咪唑-2-基)丙基] -2-(6-氟-2-羟基-1-异丙基-1,2,3,4-四氢化萘-2-基)-N - 甲基乙酰胺,将其还原成2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-1-氟丙基-1,2,3,4-四氢萘-2-酮 并将2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-1-氟丙基-1,2,3,4-四氢化萘 -2-醇与甲氧基乙酸或甲氧基乙酸的活化衍生物反应。 本发明特别适用于制备米非普利,(1S,2S)-2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-2-碘异丙基 -1,2,3,4-四氢萘-2-基甲氧基乙酸酯及其二盐酸盐。 N- [3-(1H-苯并咪唑-2-基)丙基] -N-甲基乙酰胺,和2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基 ] -6-氟-1-异丙基-1,2,3,4-四氢萘-2-醇二氧杂环己烯,是新的。

    Preparation of acyclovir using 1,3 dioxolane
    7.
    发明授权
    Preparation of acyclovir using 1,3 dioxolane 失效
    使用1,3-二氧戊环制备无环鸟苷

    公开(公告)号:US5567816A

    公开(公告)日:1996-10-22

    申请号:US426005

    申请日:1995-04-27

    IPC分类号: C07D473/00 C07D473/18

    CPC分类号: C07D473/00

    摘要: A process for the preparation of acyclovir includes contacting an at least partially silylated guanine or mixture of at least partially silylated guanines with 1,3-dioxolane in the presence of a selective alkylation catalyst selected from the group consisting of trifluoromethanesulfonic acid, trimethylsilyl trifluoromethanesulfonate, and bistrimethylsilyl sulfonate, and hydrolyzing the product thus formed.

    摘要翻译: 制备无环鸟苷的方法包括在选自烷基化催化剂的存在下使至少部分甲硅烷基化的鸟嘌呤或至少部分甲硅烷化的鸟嘌呤的混合物与1,3-二氧戊环接触,所述选择性烷基化催化剂选自三氟甲磺酸,三氟甲磺酸三甲基甲硅烷基酯和 双三甲基甲硅烷基磺酸盐,并水解由此形成的产物。

    Pyrido [2,3,d]pyrimidine derivatives
    8.
    发明授权
    Pyrido [2,3,d]pyrimidine derivatives 失效
    吡啶并[2,3,d]嘧啶衍生物

    公开(公告)号:US4845216A

    公开(公告)日:1989-07-04

    申请号:US74623

    申请日:1987-07-17

    IPC分类号: C07D471/04

    CPC分类号: C07D471/04 Y02P20/55

    摘要: 2,4-Diamino- and 2-amino-4-hydroxy- derivatives of N-(4-[2-(pyrido[2,3-d]pyrimidin-6-yl)alkyl]benzoyl)-L-glutamic acids, and the corresponding 5,6,7,8-tetrahydro compounds are antineoplastic agents. The compounds are prepared by hydrolytic or hydrogenolytic removal of carboxylic acid protecting groups from the correspondingly protected glutamic acid derivatives. A typical embodiment is N-)4-[2-(2-amino-4-hydroxy-5,6,7,8-tetrahydropyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl)-L-glutamic acid.

    摘要翻译: N-(4- [2-(吡啶并[2,3-d]嘧啶-6-基)烷基]苯甲酰基)-L-谷氨酸的2,4-二氨基 - 和2-氨基-4-羟基 - 相应的5,6,7,8-四氢化合物是抗肿瘤剂。 通过水解或氢解除去相应保护的谷氨酸衍生物的羧酸保护基来制备化合物。 典型的实施方案是N-)4- [2-(2-氨基-4-羟基-5,6,7,8-四氢吡啶并[2,3-d]嘧啶-6-基)乙基]苯甲酰基) 谷氨酸。

    Preparation of mibefradil via an acetamide anion
    10.
    发明授权
    Preparation of mibefradil via an acetamide anion 失效
    通过乙酰胺阴离子制备米非拉迪

    公开(公告)号:US5892055A

    公开(公告)日:1999-04-06

    申请号:US106058

    申请日:1998-06-26

    IPC分类号: C07D235/14

    CPC分类号: C07D235/14

    摘要: A method of preparing 2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl methoxyacetate comprises contacting 6-fluoro-1-isopropyl-3,4-dihydro-1H-naphthalen-2-one with the dianion of N-�3-(1H-benzimidazol-2-yl)propyl!-N-methylacetamide to form N-�3-(1H-benzirnidazol-2-yl) propyl!-2-(6-fluoro-2-hydroxy-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-yl)-N-methylacetamide, reducing this to 2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1,2,3,4-tetrahydronaphthalen-2-ol, and treating the 2-�2-{�3-(1H-benzirnidazol-2-yl)propyl!methylarnino}ethyl!-6-fluoro-1-isopropyl-1, 2,3,4-tetrahydronaphthalen-2-ol with methoxyacetic acid or an activated derivative of methoxyacetic acid. The invention is particularly applicable to the preparation of mibefradil, (1S,2S)-2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1, 2,3,4-tetrahydronaphthalen-2-yl methoxyacetate, and its dihydrochloride salt. N-�3-(1H-Benzimidazol-2-yl)propyl!-N-methylacetamide, and the acetic acid solvate of 2-�2-{�3-(1H-benzimidazol-2-yl)propyl!methylamino}ethyl!-6-fluoro-1-isopropyl-1, 2,3,4-tetrahydronaphthalen-2-ol dioxalate, are new.

    摘要翻译: 制备2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-1-氟-2-丙基-1,2,3,4-四氢化萘-2-酮的方法, 甲氧基乙酸甲酯包括使6-氟-1-异丙基-3,4-二氢-1H-萘-2-酮与N- [3-(1H-苯并咪唑-2-基)丙基] -N-甲基乙酰胺的二价阴离子接触到 形成N- [3-(1H-苯基咪唑-2-基)丙基] -2-(6-氟-2-羟基-1-异丙基-1,2,3,4-四氢化萘-2-基)-N- 甲基乙酰胺,将其还原成2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-1-氟丙基-1,2,3,4-四氢萘-2- - 醇,并处理2- [2 - {[3-(1H-苯基咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-1-异丙基-1,2,3,4-四氢化萘-2 - 甲氧基乙酸或甲氧基乙酸的活化衍生物。 本发明特别适用于制备米非普利,(1S,2S)-2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基] -6-氟-2-异丙基 -1,2,3,4-四氢萘-2-基甲氧基乙酸酯及其二盐酸盐。 N- [3-(1H-苯并咪唑-2-基)丙基] -N-甲基乙酰胺和2- [2 - {[3-(1H-苯并咪唑-2-基)丙基]甲基氨基}乙基的乙酸溶剂化物 ] -6-氟-1-氟丙基-1,2,3,4-四氢萘-2-醇草酸盐是新的。